主动脉瓣狭窄与全髋关节置换术并发症:围术期药物的作用
基于国家数据库的回顾性队列研究,将接受全髋关节置换术的主动脉瓣狭窄患者与非主动脉瓣狭窄患者按1:1倾向评分匹配,每组7582例,比较30天并发症。主动脉瓣狭窄患者卒中、心梗、菌血症、肺炎、输血、急性肾衰竭等风险更高;术日氨甲环酸与较低输血、假体周围感染、ICU和再入院率相关,而噻嗪类利尿剂、ACEI和β受体阻滞剂与30天卒中风险增加相关。
要点
- 主动脉瓣狭窄患者THA后30天卒中、心梗、肺炎、输血、肾衰竭和再入院风险升高。
- 术日氨甲环酸与较低输血、假体周围感染、ICU和再入院率相关,不增加心血管或血栓栓塞事件。
- 术日噻嗪类利尿剂、ACEI和β受体阻滞剂与主动脉瓣狭窄患者30天卒中风险增加相关。
核心结论
- 主动脉瓣狭窄患者接受全髋关节置换术面临更高的早期并发症风险,尤其是卒中和全身性事件。
- 围术期血流动力学优化和心血管药物管理可能有助于降低30天并发症发生率。
研究设计与样本
- 回顾性队列研究,使用国家数据库识别2006年1月至2026年1月接受全髋关节置换术的成人患者。
- 主动脉瓣狭窄患者与非主动脉瓣狭窄患者按1:1倾向评分匹配,每组7582例,比较30天并发症。
- 在主动脉瓣狭窄患者中,比较术日接受氨甲环酸与匹配未接受者的30天结局,并用Cox回归评估术日药物与30天卒中风险的关联。
主要发现
- 与匹配对照相比,主动脉瓣狭窄患者30天卒中、心肌梗死、菌血症、肺炎、输血、急性肾衰竭、急性失血后贫血、ICU治疗和再入院率均更高(均P < 0.05)。
- 在主动脉瓣狭窄患者中,术日氨甲环酸与较低的30天输血、假体周围感染、ICU治疗和再入院率相关(均P < 0.05),心血管或血栓栓塞并发症无显著差异。
- 在主动脉瓣狭窄队列中,术日噻嗪类利尿剂、血管紧张素转换酶抑制剂和β受体阻滞剂与30天卒中风险增加相关(均P < 0.05),其他评估的心血管药物类别与卒中风险无显著关联。
临床怎么用
- 对主动脉瓣狭窄患者行全髋关节置换术时,应加强围术期血流动力学优化和心血管药物管理以降低30天并发症风险。
- 术日使用氨甲环酸可能减少输血、假体周围感染、ICU治疗和再入院,且不增加心血管或血栓栓塞事件。
- 对主动脉瓣狭窄患者,术日使用噻嗪类利尿剂、ACEI或β受体阻滞剂时需警惕30天卒中风险增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Total hip arthroplasty (THA) is commonly performed in older adults who have coexisting aortic stenosis (AS), a condition associated with fixed cardiac output and limited hemodynamic reserve. This study assessed 30-day complications and the impact of day-of-surgery medications in patients who have AS undergoing THA. METHODS: A retrospective cohort study using a national database identified adults undergoing THA from January 2006 to January 2026. Individuals who had AS were propensity score-matched 1:1 to those who did not have AS, and 30-day complications were compared using risk ratios. After propensity score matching, 7,582 patients remained in each cohort. The 30-day outcomes were also compared between AS patients who received day-of-surgery tranexamic acid and matched patients who did not. Cox regressions evaluated associations between day-of-surgery medications and 30-day stroke risk within the AS cohort. RESULTS: Compared with matched controls, patients who had AS experienced higher rates of 30-day complications, including stroke, myocardial infarction, bacteremia, pneumonia, transfusion, acute renal failure, acute posthemorrhagic anemia, intensive care unit care, and readmission (all P < 0.05). Among patients who had AS, day-of-surgery tranexamic acid use was associated with lower rates of 30-day transfusion, periprosthetic joint infection, intensive care unit care, and readmission (all P < 0.05), without significant differences in cardiovascular or thromboembolic complications. Within the AS cohort, day-of-surgery thiazide diuretics, angiotensin-converting enzyme inhibitors, and beta blockers were associated with increased 30-day stroke hazard (all P < 0.05), whereas other evaluated day-of-surgery cardiovascular medication classes were not significantly associated with increased stroke risk. CONCLUSIONS: Patients who have AS undergoing THA face elevated risks of early complications, particularly stroke and systemic events. Careful perioperative hemodynamic optimization and cardiovascular medication management may help mitigate 30-day morbidity.
引用
- Hwang J, Wei R, Valencia AA, et al. Aortic Stenosis and Total Hip Arthroplasty Complications: The Role of Perioperative Medications. J Arthroplasty. 2026. PMID: 42637014. doi:10.1016/j.arth.2026.08.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。